{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/fungal-nail-infection/management/management/","result":{"pageContext":{"chapter":{"id":"36068044-ec28-5f59-b737-dd89aa53cca5","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field b5035a0e-4ee1-46ca-a4ec-448efc73cbd6 --><h2>Scenario: Management of fungal nail infection</h2><!-- end field b5035a0e-4ee1-46ca-a4ec-448efc73cbd6 -->","summary":"Covers the management of people with confirmed fungal nail infection in primary care.","htmlStringContent":"<!-- begin item 12dd29f7-30cc-481d-bb03-3ad6c84e83fd --><!-- begin field d589a2ce-6de6-4c92-9c2a-acbd00864e78 --><p>From age 12 years onwards.</p><!-- end field d589a2ce-6de6-4c92-9c2a-acbd00864e78 --><!-- end item 12dd29f7-30cc-481d-bb03-3ad6c84e83fd -->","topic":{"id":"1303927b-7e0c-517d-85e9-841c9ac02151","topicId":"d2c6135f-fef1-4a56-80dc-161c93380c7d","topicName":"Fungal nail infection","slug":"fungal-nail-infection","lastRevised":"Last revised in March 2018","chapters":[{"id":"bc563964-f1b0-559d-9f21-380162710ddf","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"dd347390-fb63-5e80-9fab-bd3cc4704341","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0cdd100c-c9d0-5685-980c-52f246d1100e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"886d32db-68df-5055-b459-55404c1f011e","slug":"changes","fullItemName":"Changes"},{"id":"c1cacd2b-dba0-5341-a274-66fd882b2036","slug":"update","fullItemName":"Update"}]},{"id":"9f0a65a3-9309-5a00-a9fa-bda2fb7a49c4","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1121797b-5555-5e24-a9ae-aabc657725dd","slug":"goals","fullItemName":"Goals"},{"id":"aa660497-e222-5e9d-b282-3069500c380f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"49df22af-d1aa-56cd-b2dc-30e6ecc84ca8","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a79a5fd4-4f6a-5d37-8714-e4bd3bea76b0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6db25a8b-db82-5b72-bade-fa216c349fd8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2515b15e-47ac-5e93-acaf-588daa2e06f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d257da5b-218f-50fc-96b1-55ec4b44f5cd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7ccd879d-9979-5f0b-b655-8da37ca04149","slug":"definition","fullItemName":"Definition"},{"id":"20d20421-b2ba-513f-87b5-3fad4f731aa5","slug":"causes","fullItemName":"Causes"},{"id":"3142330a-0287-5835-8a69-857972828fb2","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"29b083db-9488-5407-92df-43f4952d8df3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d7dd4e0b-6a97-5db7-bfa3-aa690c7974af","slug":"complications","fullItemName":"Complications"},{"id":"3a29be3f-ea9f-56a3-b8d7-78341665856e","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4346dd42-e5eb-550e-a004-7c8e7103a196","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b6a7486c-a6d8-5d8b-918c-8610bf76e212","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"eec0a81e-c0c0-5f9d-951e-f19c41cfafaf","slug":"assessment","fullItemName":"Assessment"},{"id":"d84aa70d-b236-5783-9eeb-e1181b1311f8","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"12363e3a-9d3f-54c7-8f68-1145b8f312b3","fullItemName":"Management","slug":"management","subChapters":[{"id":"36068044-ec28-5f59-b737-dd89aa53cca5","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"94da5137-b65a-5fa1-a933-bbcaa1a5c10b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6780cd52-ecfd-5eba-8c7e-66bc71b64ed2","slug":"topical-amorolfine","fullItemName":"Topical amorolfine"},{"id":"7009ace0-8da0-5da4-917e-8900ae3cc390","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"5d413d25-a998-5ee4-ad9d-be6306400282","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"}]},{"id":"0b102b3a-ebce-5c6e-9670-3610defc871d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bc0bd4bc-1b10-52dc-b942-cd4682774d01","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"dc202e28-37b1-5789-a14a-b5a0850d8cf8","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"49993e8c-ae7a-5891-bf43-21a6406ce1b5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b6aa45b7-d833-599f-8bcc-4d08c6c264bb","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2805cbb7-09b5-5875-a0c1-c501223c6ab3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"595745a2-d654-5e3b-850e-eac6532bd5db","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"74af204e-7571-5d05-963f-0c0614335fbf","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"12363e3a-9d3f-54c7-8f68-1145b8f312b3","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"d06ec51b-07b0-560f-b912-5fd871420732","slug":"initial-management","fullItemName":"Initial management","depth":3,"htmlHeader":"<!-- begin field d8920026-2424-4e23-89f9-a059af303646 --><h3>How should I initially manage confirmed fungal nail infection?</h3><!-- end field d8920026-2424-4e23-89f9-a059af303646 -->","summary":null,"htmlStringContent":"<!-- begin item 6df01bd8-72fd-4bb6-8a92-4b1efb5fd989 --><!-- begin field 068391f7-7bcf-4368-b629-52c28adbdc7a --><p><strong>The management of fungal nail infection depends on the site and severity of nail involvement, the causative organism, the person's symptoms, and any co-morbidities.</strong></p><ul><li><strong>Advise on self-care management strategies:</strong><ul><li>Keep nails trimmed short and filed down. Avoid sharing toenail clippers with family members.</li><li>Wear well-fitting non-occlusive shoes, without high heels or narrow toes. Consider replacing old footwear which could be contaminated with fungal spores.</li><li>Wear cotton, absorbent socks.</li><li>Maintain good foot hygiene, including prompt treatment of any associated tinea pedis. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/fungal-skin-infection-foot/\">Fungal skin infection - foot</a> for more information.</li><li>Wear protective footwear when using communal bathing places, locker rooms, and gymnasiums, to avoid re-exposure.</li><li>Avoid prolonged or frequent exposure to warm, damp conditions if possible.</li><li>Avoid trauma to the nails if possible.</li></ul></li><li><strong>Provide information on sources of advice and support, such as:</strong><ul><li>The British Association of Dermatologists information leaflet <a data-hyperlink-id=\"9ce2088d-85fb-4066-9546-a98d012c5164\" href=\"http://www.bad.org.uk/shared/get-file.ashx?id=205&itemtype=document\" target=\"_blank\">Fungal infections of the nails</a>.</li><li>The NHS information on <a data-hyperlink-id=\"763c6204-398a-45be-9e25-a98d012c5177\" href=\"https://www.nhs.uk/conditions/fungal-nail-infection/\" target=\"_blank\">Fungal nail infection</a>.</li></ul></li><li><strong>Advise that antifungal treatment is not needed if:</strong><ul><li>The person is not troubled by the appearance of the nail(s), and/or</li><li>Infection is asymptomatic.</li></ul></li><li><strong>Advise on the option of antifungal treatment if:</strong><ul><li>Walking is uncomfortable.</li><li>There is significant psychological distress due to the cosmetic appearance of the nail(s).</li><li>There are <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/background-information/risk-factors/\">co-morbid conditions</a> which increase the risk of <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/background-information/complications/\">complications</a>.</li><li>Nail infection is a potential source of associated fungal skin infection. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/fungal-skin-infection-body-groin/\">Fungal skin infection - body and groin</a>, <a class=\"topic-reference external-reference\" href=\"/topics/fungal-skin-infection-foot/\">Fungal skin infection - foot</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/fungal-skin-infection-scalp/\">Fungal skin infection - scalp</a> for more information.</li></ul></li><li><strong>If dermatophyte or <em>Candida</em> nail infection is <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/diagnosis/assessment/\">confirmed</a>, advise on the option of topical antifungal treatment in adults if there is:</strong><ul><li>Up to 50% involvement of the distal nail plate without nail matrix involvement.</li><li>Up to two affected nails.</li><li>Early, mild distal or lateral onychomycosis.</li><li>Superficial white onychomycosis.</li><li>A contraindication to oral antifungal treatment. See the sections on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/prescribing-information/oral-terbinafine/\">Oral terbinafine</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/prescribing-information/oral-itraconazole/\">Oral itraconazole</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/prescribing-information/\">Prescribing information</a> for more information.</li></ul></li><li><strong>If topical treatment is appropriate, advise on the use of amorolfine 5% nail lacquer:</strong><ul><li>This can be purchased over-the-counter and is applied once or twice weekly to the affected nail(s) after gentle nail filing.<ul><li>Treatment should be continued for 6 months for fingernails and 9–12 months for toenails.</li><li>If there is <em>Candida</em> infection with associated paronychia, topical treatment should also be applied to the area of paronychia.</li><li>Advise the person to avoid cosmetic nail varnishes or artificial nails during treatment.</li><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/prescribing-information/topical-amorolfine/\">Topical amorolfine</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/prescribing-information/\">Prescribing information</a> for more information.</li></ul></li><li>Advise that the use of other topical treatments such as tea tree oil is not recommended.</li></ul></li><li><strong>If self-care measures alone and/or topical treatment is not successful or appropriate, advise on the option of </strong><strong><a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/management/management/#oral-antifungal-treatment\">oral antifungal treatment</a></strong><strong>.</strong></li></ul><!-- end field 068391f7-7bcf-4368-b629-52c28adbdc7a --><!-- end item 6df01bd8-72fd-4bb6-8a92-4b1efb5fd989 -->","subChapters":[{"id":"0bcba6d5-c62a-5835-9a23-9b6f0a07efed","slug":"basis-for-recommendation-e3d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 97053810-614e-45d5-a986-e5ef99840b3e --><h4>Basis for recommendation</h4><!-- end field 97053810-614e-45d5-a986-e5ef99840b3e -->","summary":null,"htmlStringContent":"<!-- begin item e3df210c-811a-4cf7-9a55-b72651226ef0 --><!-- begin field 425ca88d-b086-4f3f-9f93-5956ad20405f --><p>The recommendations on self-care strategies and topical antifungal treatment are based on expert opinion in the British Association of Dermatologists' (BAD) <em>Guidelines for the management of onychomycosis 2014</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>], a network meta-analysis of onychomycosis treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Gupta, 2015</a>], a meta-analysis of combination treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Feng, 2017</a>], and expert opinion in review articles on fungal nail infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Westerberg, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Gupta, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Tosti, 2016</a>] and in the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">BNF 75, 2018</a>]. </p><h5>Advice on self-care strategies</h5><ul><li>The recommendations on self-care strategies to help manage infection and reduce the risk of re-infection are based on expert opinion in the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>] and in a review article on minimizing disease relapse and recurrence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Tosti, 2016</a>].<ul><li>The recommendation to discard old footwear is based on the fact that this may contain a fungal reservoir, which can cause fungal reinfection.</li></ul></li></ul><h5>Offering topical antifungal monotherapy</h5><ul><li>The recommendation on considering topical antifungal treatment for adults (not children) is based on the fact that topical treatment is not licensed for use in children, and there is no evidence for efficacy in this population group in clinical trials [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>]. The PHE publication also recommends not treating children in primary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">PHE, 2017</a>].</li><li>The recommendation to confirm the diagnosis of fungal nail infection with fungal microscopy and culture before starting antifungal treatment is based on expert opinion in the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>].<ul><li>This may help to exclude alternative non-fungal conditions which may present similarly, to detect mixed infections, and to identify specific causative organisms which need treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>].</li></ul></li><li>The recommendations on when to consider topical antifungal monotherapy are based on limited evidence and expert opinion in the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>], a network meta-analysis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Gupta, 2015</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Gupta, 2014</a>] and the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">BNF 75, 2018</a>].<ul><li>Amorolfine has broad-spectrum fungicidal and fungistatic activity, and is fungicidal against <em>Candida albicans</em> and the dermatophyte <em>Trichophyton mentagrophytes</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>]. It is less effective against non-dermatophyte infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Gupta, 2014</a>]. Expert opinion in the BAD guidelines and a review article note that the indications for topical antifungal treatment are limited as the hard keratin and compact structure of the dorsal nail plate act as a barrier to drug diffusion into and through the nail plate [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Gupta, 2014</a>].</li><li>A network meta-analysis of 19 randomized controlled trials (RCTs) of various treatments for dermatophyte infection found topical amorolfine was significantly superior in efficacy to placebo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Gupta, 2015</a>].</li></ul></li><li>The recommendations on the duration and frequency of topical treatment are largely based on the BAD guidelines and the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">BNF 75, 2018</a>].<ul><li>CKS notes that the PHE publication recommends a 12-month treatment course for toenails if there is confirmed superficial dermatophyte or <em>Candida</em> infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">PHE, 2017</a>].</li><li>The BAD guidelines state that once-weekly application is as effective as twice-weekly application. The BNF recommends treatment once or twice weekly.</li></ul></li><li>The recommendation to avoid commercial nail varnishes and artificial nails during treatment is based on expert opinion in the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">BNF 75, 2018</a>] and the manufacturers' Summary of Product Characteristics (SPC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">ABPI Medicines Compendium, 2013</a>].</li><li>The recommendation on not offering other topical treatments such as tea tree oil is based on expert opinion in a review article, which states that combined data from studies did not demonstrate significant benefit from this preparation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Westerberg, 2013</a>].</li></ul><!-- end field 425ca88d-b086-4f3f-9f93-5956ad20405f --><!-- end item e3df210c-811a-4cf7-9a55-b72651226ef0 -->","subChapters":[]}]},{"id":"64d47740-91b2-5918-82ee-b394510b8f6e","slug":"oral-antifungal-treatment","fullItemName":"Oral antifungal treatment","depth":3,"htmlHeader":"<!-- begin field 6d3c66d4-1382-4c73-b5c6-4228554e4742 --><h3>When should I offer oral antifungal treatment?</h3><!-- end field 6d3c66d4-1382-4c73-b5c6-4228554e4742 -->","summary":null,"htmlStringContent":"<!-- begin item 823e6087-31ea-4d41-be05-ec976c9b57b1 --><!-- begin field baa9b5d6-9072-4f2e-9782-05077e70f5d5 --><p><strong>Offer treatment with an oral antifungal agent if an adult has confirmed fungal nail infection and <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/management/management/#initial-management\">self-care measures</a> alone and/or <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/management/management/#initial-management\">topical treatment</a> are not successful or appropriate.</strong></p><ul><li><strong>If dermatophyte nail infection is <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/diagnosis/assessment/\">confirmed</a>:</strong><ul><li>Prescribe oral terbinafine first-line.<ul><li>Prescribe 250 mg once a day for between 6 weeks and 3 months for fingernails, and for 3–6 months for toenails.</li><li>Advise the person that visible improvement may be seen after the end of 2 months of fingernail treatment and 3 months of toenail treatment.</li><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/prescribing-information/oral-terbinafine/\">Oral terbinafine</a> in the section on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/prescribing-information/\">Prescribing information</a> for more detailed information.</li></ul></li><li>Prescribe oral itraconazole if an alternative drug is indicated.<ul><li>Prescribe as pulsed therapy 200 mg twice a day for 1 week, with subsequent courses repeated after a further 21 days.</li><li>Prescribe two pulses for fingernails and three pulses for toenails.</li><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/prescribing-information/oral-itraconazole/\">Oral itraconazole</a> in the section on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/prescribing-information/\">Prescribing information</a>  for more detailed information.</li></ul></li><li>Consider the use of griseofulvin if terbinafine and itraconazole use is contraindicated.</li></ul></li><li><strong>If <em>Candida</em> or non-dermatophyte nail infection is <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/diagnosis/assessment/\">confirmed</a>: </strong><ul><li>Prescribe oral itraconazole first-line.<ul><li>Prescribe as pulsed therapy 200 mg twice a day for 1 week, with subsequent courses repeated after a further 21 days.</li><li>Prescribe two pulses for fingernails and three pulses for toenails.</li><li>Be aware that the use of itraconazole for non-dermatophyte infections is off-label.</li><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/prescribing-information/oral-itraconazole/\">Oral itraconazole</a> in the section on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/prescribing-information/\">Prescribing information</a> for more detailed information.</li></ul></li><li>Prescribe oral terbinafine if an alternative drug is indicated.<ul><li>Prescribe 250 mg once a day for between 6 weeks and 3 months for fingernails, and for 3–6 months for toenails.</li><li>Be aware that the use of terbinafine for non-dermatophyte infections is off-label.</li><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/prescribing-information/oral-terbinafine/\">Oral terbinafine</a> in the section on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/prescribing-information/\">Prescribing information</a>  for more detailed information.</li></ul></li><li>Consider the use of griseofulvin if terbinafine and itraconazole are not tolerated or are contraindicated.</li><li>Treat any associated paronychia. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/paronychia-acute/\">Paronychia - acute</a> for more information.</li></ul></li><li><strong>Monitor for any subsequent nail growth 3–6 months after the start of treatment.</strong><ul><li>Consider filing a notch at the base of the most abnormal nail when starting oral antifungal treatment — this can help future comparisons of old with new nail growth.</li><li>Advise that serial photographs may also help monitor nail growth.<ul><li>If abnormal nail remains distal to the notch as it grows out, no further treatment is required.</li><li>If abnormal nail moves proximal to the notch, this indicates ongoing infection and further treatment is needed.</li></ul></li><li>If normal nail regrowth does not occur, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/management/management/#treatment-failure\">Treatment failure</a> for further management options.</li></ul></li></ul><!-- end field baa9b5d6-9072-4f2e-9782-05077e70f5d5 --><!-- end item 823e6087-31ea-4d41-be05-ec976c9b57b1 -->","subChapters":[{"id":"06bda29d-6c77-5150-927b-f3eb6fcf8d9f","slug":"basis-for-recommendation-097","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a0373944-4fdc-4a21-b98e-6934d281c8ad --><h4>Basis for recommendation</h4><!-- end field a0373944-4fdc-4a21-b98e-6934d281c8ad -->","summary":null,"htmlStringContent":"<!-- begin item 09772753-f3f1-424a-967d-b6c445081a76 --><!-- begin field b071d6aa-cd4b-4c96-8b74-1320bd7423e0 --><p>The recommendations on oral antifungal treatment are based on expert opinion in the British Association of Dermatologists' (BAD) <em>Guidelines for the management of onychomycosis 2014</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>], the Public Health England (PHE) publication <em>Fungal skin and nail infections: Diagnosis and laboratory investigation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">PHE, 2017</a>], a Cochrane systematic review <em>Oral antifungal medication for toenail onychomycosis (Review)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Kreijkamp-Kaspers, 2017</a>], a network meta-analysis of onychomycosis treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Gupta, 2015</a>], a meta-analysis of combination treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Feng, 2017</a>], and expert opinion in review articles on fungal nail infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Westerberg, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">de Sa, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>] and in the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">BNF 75, 2018</a>].</p><ul><li>The recommendation on considering oral antifungal treatment for adults (not children) is based on the fact that terbinafine and itraconazole are not licensed for use in children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>]. The PHE publication also recommends not treating children in primary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">PHE, 2017</a>].</li><li>The recommendation on confirming the diagnosis of fungal nail infection with fungal microscopy and culture before starting antifungal treatment is based on expert opinion in the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>], the PHE publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">PHE, 2017</a>], and in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>].<ul><li>This may be helpful to exclude alternative non-fungal conditions which may present similarly, to detect mixed infections, and to identify specific causative organisms which need treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>].</li></ul></li></ul><h5>Offering oral terbinafine treatment</h5><ul><li>The recommendation to offer terbinafine first-line for dermatophyte infection is based on expert opinion in the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>], the PHE publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">PHE, 2017</a>], a network meta-analysis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Gupta, 2015</a>], a Cochrane systematic review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Kreijkamp-Kaspers, 2017</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">de Sa, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>].<ul><li>Terbinafine is both fungistatic and fungicidal, and is particularly fungicidal against the dermatophytes <em>Trichophyton rubrum</em> and <em>Trichophyton mentagrophytes</em>. It has lower fungistatic activity against <em>Candida</em> species than the azoles, such as itraconazole [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>].</li><li>The BAD guidelines state that terbinafine should be used first-line for dermatophyte infections due to its higher efficacy and tolerability compared with other oral preparations. Terbinafine also has a lower risk of drug interactions than itraconazole and has a long half-life, persisting in the nail for 6 months after the completion of treatment. In addition, studies have found lower recurrence rates with terbinafine compared with itraconazole when treating dermatophyte infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>].</li><li>This is supported by a network meta-analysis of 19 randomized controlled trials (RCTs) of various treatments for dermatophyte infection, which found that terbinafine and pulsed itraconazole regimens had the greatest relative odds ratios of mycological cure when compared with various other oral and topical antifungal agents. CKS notes that clinical cure rates were not considered due to different definitions of this outcome across trials [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Gupta, 2015</a>].</li><li>A Cochrane systematic review of oral antifungal treatments for toenail onychomycosis analysed 48 RCTs (n = 10,200, 47/48 studies assessed dermatophyte infections) and found [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Kreijkamp-Kaspers, 2017</a>]:<ul><li>High-quality evidence that terbinafine is more effective than placebo for achieving clinical and mycological cure.</li><li>Moderate-quality evidence that terbinafine was probably more effective than azoles such as itraconazole for achieving clinical and mycological cure, with the same risk of adverse events.</li><li>Low-quality evidence that terbinafine may lower the recurrence rate when compared with placebo.</li></ul></li></ul></li><li>The recommendations on the dosage instructions for terbinafine are based on expert opinion in the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>], a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">de Sa, 2014</a>], and the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">BNF 75, 2018</a>].</li></ul><h5>Offering oral itraconazole treatment</h5><ul><li>The recommendation to offer itraconazole first-line for <em>Candida</em> and non-dermatophyte infection is based on expert opinion in the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>], the PHE publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">PHE, 2017</a>], a Cochrane systematic review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Kreijkamp-Kaspers, 2017</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">de Sa, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>].<ul><li>Itraconazole is a fungistatic agent and is active against yeasts, dermatophytes, and some non-dermatophyte moulds [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>].</li><li>The BAD guidelines note that <em>in vitro</em> susceptibility testing has shown that the non-dermatophyte <em>Aspergillus</em> has excellent susceptibility to itraconazole, and studies have found itraconazole has significantly greater efficacy than terbinafine for the treatment of <em>Candida</em> nail infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>].</li><li>Itraconazole concentrates and persists in the nail plate, resulting in intermittent pulsed dosing regimes being as effective as continuous daily dosing [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>]. In addition, it has a long half-life, persisting in the nail for 6–9 months after the completion of treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>].</li><li>A Cochrane systematic review of oral antifungal treatments for toenail onychomycosis analysed 48 RCTs (n = 10,200, 47/48 studies assessed dermatophyte infections) and found [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Kreijkamp-Kaspers, 2017</a>]:<ul><li>High-quality evidence that azoles are more effective than placebo for achieving clinical and mycological cure.</li><li>Low-quality evidence that azoles may lower the recurrence rate when compared with placebo.</li></ul></li><li>Expert opinion in a review article notes that non-dermatophyte moulds are difficult to treat and may be a reason for treatment failure [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>].</li></ul></li><li>The recommendations on the dosage instructions for itraconazole are based on expert opinion in the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">BNF 75, 2018</a>].</li></ul><h5>Considering oral griseofulvin treatment</h5><ul><li>Griseofulvin is no longer a treatment of choice for the management of fungal nail infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>]. The recommendation to consider offering griseofulvin treatment as an alternative option to terbinafine and itraconazole if these drugs are contraindicated is based on expert opinion in the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">de Sa, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>].<ul><li>Griseofulvin has lower efficacy and higher relapse rates compared with the other agents, and may need longer treatment courses [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>].</li><li>In addition, there is a higher incidence of adverse effects with griseofulvin treatment compared with other oral antifungal agents, leading to lower compliance rates [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>].</li></ul></li><li>A Cochrane systematic review of oral antifungal treatments for toenail onychomycosis analysed 48 RCTs (n = 10,200, 47/48 studies assessed dermatophyte infections) and found [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Kreijkamp-Kaspers, 2017</a>]:<ul><li>Moderate-quality evidence that the risk of adverse effects was probably higher in the griseofulvin group compared with the azole group.</li></ul></li></ul><h5>Monitoring for nail growth</h5><ul><li>The recommendation on checking for nail growth 3–6 months after the start of treatment is based on expert opinion in the BAD guidelines and in a review article, as this is the time period needed for outgrowth of healthy nail, and the optimal clinical effect is seen months after mycological cure and stopping antifungal treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>].</li><li>The recommendation on using serial photography to monitor nail growth is based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>].</li><li>The recommendations on the need for ongoing treatment depending on nail regrowth are based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>].</li></ul><!-- end field b071d6aa-cd4b-4c96-8b74-1320bd7423e0 --><!-- end item 09772753-f3f1-424a-967d-b6c445081a76 -->","subChapters":[]}]},{"id":"4500d449-3b84-5cfb-9122-9531d0ee3689","slug":"treatment-failure","fullItemName":"Treatment failure","depth":3,"htmlHeader":"<!-- begin field b413640a-6941-456b-81d3-2cf99bc60ff8 --><h3>How should I manage treatment failure?</h3><!-- end field b413640a-6941-456b-81d3-2cf99bc60ff8 -->","summary":null,"htmlStringContent":"<!-- begin item dd9ae3e3-8b17-4157-bd1a-005cfb863826 --><!-- begin field 2f708dc7-8441-4db5-b309-001bcaffe996 --><ul><li><strong>If normal <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/management/management/#oral-antifungal-treatment\">nail regrowth</a> does not occur after <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/management/management/#oral-antifungal-treatment\">oral antifungal treatment</a> and there are signs of treatment failure:</strong><ul><li>Consider and, if possible, manage any <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/background-information/prognosis/\">underlying cause</a> of treatment failure.</li><li>Consider arranging <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/diagnosis/assessment/#taking-nail-samples\">re-sampling</a> for nail clippings and/or scrapings for fungal microscopy and culture. </li><li>Consider the use of combination treatment with a <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/management/management/#initial-management\">topical</a> <em>and</em> <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-nail-infection/management/management/#oral-antifungal-treatment\">oral antifungal</a> agent.</li><li>Note: be aware that the nail's appearance may not be restored to normal, even after successful eradication of infection.</li></ul></li><li><strong>Consider arranging referral to a podiatrist if:</strong><ul><li>Thickened toenails cause discomfort when walking.</li><li>There is nail trauma due to the person's footwear.</li><li>Deformed toenails are traumatizing adjacent toes.</li></ul></li><li><strong>Consider arranging referral to a paediatric dermatologist if:</strong><ul><li>Oral antifungal treatment is being considered for a child.</li></ul></li><li><strong>Consider arranging referral to a dermatologist if:</strong><ul><li>The diagnosis is uncertain.</li><li>Treatment in primary care is unsuccessful.</li><li>There is co-existent nail disease, such as psoriasis or lichen planus.</li><li>The person is immunocompromised, depending on clinical judgement.</li></ul></li></ul><!-- end field 2f708dc7-8441-4db5-b309-001bcaffe996 --><!-- end item dd9ae3e3-8b17-4157-bd1a-005cfb863826 -->","subChapters":[{"id":"7ddb4090-0832-54eb-a98a-f224b3029009","slug":"basis-for-recommendation-d3d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 1aa2d0b1-8f2a-436f-8ced-e1411b1738a6 --><h4>Basis for recommendation</h4><!-- end field 1aa2d0b1-8f2a-436f-8ced-e1411b1738a6 -->","summary":null,"htmlStringContent":"<!-- begin item d3d3ec3d-ff33-4fe0-82a6-f66f931bee41 --><!-- begin field 97452a99-f650-465f-9700-129604039a3e --><p>The recommendations on treatment failure are based on the British Association of Dermatologists' (BAD) <em>Guidelines for the management of onychomycosis 2014</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>], the Public Health England (PHE) publication <em>Fungal skin and nail infections: Diagnosis and laboratory investigation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">PHE, 2017</a>], a meta-analysis of combination treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Feng, 2017</a>], and expert opinion in review articles on fungal nail infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Westerberg, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>] and in the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">BNF 75, 2018</a>].</p><h5>Considering combination topical and oral antifungal treatment</h5><ul><li>The recommendation on considering a combination of topical and oral antifungal treatment is based on limited and conflicting evidence cited in the BAD guidelines, which suggests this approach may be particularly relevant for non-dermatophyte infections that are resistant to standard oral antifungal monotherapy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>].</li><li>This is supported by a meta-analysis of the efficacy and tolerability of topical amorolfine in combination with oral antifungals (five RCTs, n = 713), which found combination treatment can result in a greater likelihood of complete clearance (both clinical and mycological cure) of onychomycosis compared with oral antifungal monotherapy, with no increase in adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Feng, 2017</a>].<ul><li>It suggests that topical antifungals such as amorolfine may increase the efficacy of oral antifungals, offering a more rapid cure and preventing relapses.</li><li>CKS notes that there were various limitations to this study including non-standardized follow-up times and treatment courses in different trials.</li></ul></li></ul><h5>Arranging referral to podiatry</h5><ul><li>Podiatry may be able to obtain improved specimens for fungal culture, such as using a sharp curette to obtain material from the nail bed close to the lanula, or obtaining a superficial punch biopsy of the proximal nail plate [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>]. This may help to identify whether treatment failure is due to repeat infection or another fungal strain [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>].</li><li>Podiatry may be able to perform chemical or surgical avulsion (complete removal) or debridement (partial removal) of the affected nail, which may be particularly useful in severe disease and extensive nail thickening [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>].<ul><li>These procedures may help to reduce fungal mass (for example dermatophytomas) and increase the penetration of antifungal treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>]. They may also be useful in the management of non-dermatophyte infections that are resistant to standard oral antifungal monotherapy. Improved outcomes may be seen with combination treatment of antifungal therapy with intermittent nail debridement or avulsion.</li><li>This approach is supported by expert opinion in a review article which states that oral antifungal treatment with concomitant nail debridement increases cure rates further [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Westerberg, 2013</a>].</li><li>Rarely, people may elect to undergo permanent nail removal if they have refractory fungal infection or frequent recurrences [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Westerberg, 2013</a>].</li></ul></li><li>Podiatry may also be able to provide advice on appropriate footwear and orthotic devices if there is nail trauma due to footwear or deformed toes.</li></ul><h5>Arranging referral to dermatology</h5><ul><li>The recommendations on when to consider referral to dermatology are based on the PHE publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">PHE, 2017</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>].<ul><li>Dermatology may be able to obtain improved specimens for fungal culture, such as using a sharp curette to obtain material from the nail bed close to the lanula, or obtaining a superficial punch biopsy of the proximal nail plate [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>]. This may help to identify whether treatment failure is due to repeat infection or another fungal strain [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>].</li><li>The recommendation on arranging referral for all children is largely based on the PHE publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">PHE, 2017</a>] and is extrapolated from expert opinion in the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">BNF 75, 2018</a>].<ul><li>Fungal nail infection is rare in children, oral antifungal treatments are off-label in this age-group, topical antifungal treatments are often ineffective and are off-label in children under 12 years of age, so treatment should be initiated by a specialist.</li></ul></li><li>The recommendation on considering referral for immunocompromised people is extrapolated from expert opinion in the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>] and in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>].<ul><li>This population group are more likely to have severe, refractory infection including non-dermatophyte infection which does not respond to standard treatment in primary care, and they are at increased risk of complications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>].</li><li>They may also need prolonged antifungal treatment courses and may have drug resistance to standard antifungal treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Ameen, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Eisman, 2014</a>].</li></ul></li></ul></li></ul><!-- end field 97452a99-f650-465f-9700-129604039a3e --><!-- end item d3d3ec3d-ff33-4fe0-82a6-f66f931bee41 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}